Vetter is expanding its commercial manufacturing network with plans to add ten new filling lines as pharmaceutical and biotechnology companies seek greater production capacity for increasingly complex drug products. The Contract Development and Manufacturing Organization (CDMO) is implementing the investment as part of a long-term expansion program designed to increase its ability to support customers across international markets.
The ten lines will be introduced in phases rather than through a single capacity expansion. Seven will be installed across Vetter’s existing manufacturing facilities, while the remaining three are planned for a new commercial site in Saarlouis, Germany. The first of the new lines, which is designed to fill pre-sterilized syringes, has already become operational.
A second line is expected to begin operations by the end of 2026, followed by five additional aseptic manufacturing lines scheduled through 2028. The final three lines are planned for the Saarlouis facility, which Vetter expects to bring into operation by 2031. The timeline gives the company a multi-year path for increasing fill-and-finish capacity while expanding its manufacturing footprint.
Existing Facilities Lead Vetter’s Capacity Expansion
Vetter’s decision to introduce most of the new lines at existing sites allows the company to increase production resources in stages while continuing to build its longer-term network. The first operational line is focused on pre-sterilized syringes, a format widely used for injectable medicines and biologic products.
The next wave of investment will focus on aseptic production. Five new lines are planned to become available through 2028, adding manufacturing resources for customers that require sterile filling capabilities. The phased schedule is intended to make additional capacity available over several years rather than waiting for the completion of a single large facility.
For pharmaceutical and biotech companies, access to commercial fill-and-finish capacity can become an important consideration as drug candidates progress from development into larger-scale production. Manufacturing requirements can also change during a product’s lifecycle, making flexibility and the ability to scale production important factors when selecting a CDMO partner.
Henryk Badack, managing director at Vetter, said customers are looking for manufacturing partners with established operational experience and the ability to support drug products from current requirements through future stages of development and commercialization.
The company’s investment extends beyond filling equipment. Vetter is also expanding supporting infrastructure across its operations, including compounding, pharmaceutical storage and visual inspection capabilities.
These supporting functions are important components of commercial sterile manufacturing. Increasing capacity in one part of the production process can create bottlenecks elsewhere if storage, preparation, inspection or related infrastructure does not expand at a similar pace. Vetter’s broader investment program is therefore aimed at developing its manufacturing operations as an integrated network.
The company is also introducing advanced cleanroom technology, along with increased automation and digitalization. These investments are intended to support production efficiency and consistent manufacturing operations as the network grows.
The expansion comes at a time when pharmaceutical manufacturers are managing a diverse pipeline of injectable and biologic products. Changes in drug formats, production volumes and market requirements can make manufacturing capacity planning increasingly important for companies preparing commercial launches.
Saarlouis Site Extends Long-Term Manufacturing Footprint
Vetter’s planned Saarlouis facility represents the longer-term component of the expansion. Three of the ten new commercial filling lines are scheduled for the site, which is expected to become operational in 2031.
While the existing facilities will provide the majority of the near-term capacity additions, Saarlouis is positioned to extend the company’s commercial manufacturing network into the next decade. The site will form part of Vetter’s strategy for supporting future customer demand as pharmaceutical and biotech companies advance new products into international markets.
Carsten Press, managing director at Vetter, said the phased approach allows the company to bring additional capacity online while expanding the production network in a controlled manner. He added that the investments are intended to provide scalable operations, managed supply chains and aseptic manufacturing capabilities for customers’ long-term requirements.
The investment also gives Vetter a longer planning horizon for its manufacturing infrastructure. Instead of relying solely on short-term additions, the company is combining upgrades at established facilities with the development of a new commercial location.
For customers, the value of the expansion will extend beyond the number of filling lines. A broader network can provide additional options for production planning, while expanded storage, compounding and inspection capabilities can help support different stages of a product’s manufacturing process.
The planned introduction of the lines will also allow Vetter to increase capacity progressively. The first line is already operational, another is scheduled for 2026, and five more are expected through 2028. This creates a series of capacity additions before the Saarlouis facility contributes its planned lines in 2031.
Vetter’s investment strategy reflects the capital-intensive nature of pharmaceutical manufacturing, where sterile production requires specialized facilities, equipment and quality systems. Expanding these capabilities requires long-term planning because new lines and facilities can take several years to design, qualify and bring into commercial operation.
The company has not disclosed a total financial value for the ten-line expansion. However, the scale and duration of the program indicate that Vetter is planning its manufacturing infrastructure around demand expected to develop over multiple years.
With its existing sites receiving seven new lines and the future Saarlouis location adding three more, Vetter is building a capacity pipeline that stretches into the next decade. The combination of new filling resources, expanded supporting infrastructure, automation and cleanroom technology is intended to give pharmaceutical and biotech customers additional manufacturing options as their products move through development and commercialization.
The first new line is already producing, while the remaining investments will be introduced in stages. This approach allows Vetter to expand its commercial fill-and-finish network while continuing to develop the infrastructure needed to support a growing portfolio of drug products worldwide.
